REMARKS

Claims 19-29 have been canceled without prejudice or disclaimer. Claims 30-53 have been added and therefore are pending in the present application. Claims 30-53 are supported by original claims 1-18. The hybridization conditions recited in claims 41-43 are supported by page 24, lines 20-26 of the specification.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 13, 2001

Elias J. Lambiris, Reg. No. 33,728 Novozymes North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123